PHASE I/II, MULTICENTER, OPEN-LABEL, CLINICAL AND PHARMACOKINETIC STUDY OF LURBINECTEDIN (PM01183) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPED SMALL CELL LUNG CANCER (THE LUPER STUDY)
2019-002261-35CANCER DE PULMON MICROCITICOFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
